Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01963403 · ClinicalTrials.gov registry record · Phase 4
Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive
A Phase 4 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT01963403 is a Phase 4 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 26 participants.
The verdict
NCT01963403, a Phase 4 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
This double-blinded, placebo-controlled, randomized trial will compare the effects of the use of a combined oral contraceptive pill to a placebo pill for women who are experiencing irregular and/or heavy bleeding associated with the use of an etonogestrel (ETG) implant. The hypothesis of the study is: * Use of combined oral contraceptive will significantly improve bleeding patterns for users of ETG implant * Continuation rate of ETG implant users will be increased by use of combined oral contraceptive in women desiring ETG implant removal because of the undesirable bleeding * Adverse events will be uncommon and acceptable to women who use a combined oral contraceptive with the ETG implant
Interventions
- DRUG Placebo
- DRUG EE 30mcg/LNG 150mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01963403
The ClinicalTrials.gov registry entry for NCT01963403 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01963403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01963403 about?
NCT01963403 is a clinical study titled "Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive". This double-blinded, placebo-controlled, randomized trial will compare the effects of the use of a combined oral contraceptive pill to a placebo pill for women who are experiencing irregular and/or heavy bleeding associated with the use of an etonogestrel (ETG) implant. The hypothesis of the study ...
What is the current status of trial NCT01963403?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2013-12. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01963403?
The interventions under investigation include: Placebo (DRUG), EE 30mcg/LNG 150mcg (DRUG).
Who is sponsoring clinical trial NCT01963403?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.